29958537694: Difference between revisions
From Verified Handles
company
29958537694
									
									29958537694
 (UCB)  | 
				 (AB-V1)  | 
				||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:UCB}}  | {{DISPLAYTITLE:UCB}}  | ||
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small>  | UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small>  | ||
{|  | {{SF|  | ||
{{Twt|ucb_news}}  | {{Twt|ucb_news}}  | ||
{{Twt|UCBUSA}}  | {{Twt|UCBUSA}}  | ||
{{Wb|http://www.ucb.com/|ucb.com}}  | {{Wb|http://www.ucb.com/|ucb.com}}  | ||
|}  | }}  | ||
{{IDF|  | |||
{{Isni|000000012154737X}}  | |||
}}  | |||
{{VIAF|127775358}}  | |||
{{VHID|29958537694}}{{#subtitle: <big>company</big>}}  | |||
{{#subtitle: <big>company</big>}}  | |||
Latest revision as of 17:18, 27 February 2022
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. from Wikipedia
| Icon | Service | Username | |
|---|---|---|---|
| @ucb_news | |||
| @UCBUSA | |||
| Website | ucb.com | 
Additional identifiers
These are provided for reference and have been verified to be accurate.
| Icon | Database | Identifier | |
|---|---|---|---|
| ISNI | 000000012154737X | 



